MDT Analyst Estimates: Price Targets, Revenue, Net Income, and EBIT Forecast - Medtronic PLC - Alpha Spread

First Time Loading...

Watchlist Manager

Watchlist

Price: 80.89 USD 0.81%

Updated:

Section:

Wall Street
Price Targets

Wall Street analysts forecast MDT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MDT is 95.99 USD with a low forecast of 75.75 USD and a high forecast of 109.2 USD.

MDT Lowest Forecast

Wall Street Target

MDT Average Forecast

Wall Street Target

MDT Highest Forecast

Wall Street Target

6% Downside

19% Upside

35% Upside

The latest public price target was made on Sep 13, 2023 by Larry Biegelsen from Wells Fargo , who expects MDT stock to rise by 26% over the next 12 months. You can read more about this price target by viewing the article on Benzinga.

Analyst	Price Target	Date	Article
Larry Biegelsen Wells Fargo	102 USD Upside 26%	7 months ago Sep 13, 2023	These 3 Health Care Stocks With Over 3% Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts Benzinga
David Rescott Robert W. Baird	90 USD Upside 11%	8 months ago Aug 10, 2023	Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks Delivering High-Dividend Yields Benzinga
Larry Biegelsen Wells Fargo	100 USD Upside 24%	9 months ago Jul 12, 2023	These 3 Health Care Stocks Delivering High-Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts Benzinga

Price Target	102 USD
Upside/Downside	26%

Price Target	90 USD
Upside/Downside	11%

Price Target	100 USD
Upside/Downside	24%

Stratec SE

17% Upside

Mehow Innovative Ltd

63% Upside

Qingdao Haier Biomedical Co Ltd

78% Upside

Zomedica Corp

211% Upside

Stratec SE

17% Upside

Mehow Innovative Ltd

63% Upside

Qingdao Haier Biomedical Co Ltd

78% Upside

Zomedica Corp

211% Upside

Genoray Co Ltd

503% Upside

Terumo Corp

13% Upside

Dexcom Inc

23% Upside

JEOL Ltd

28% Upside

Revenue
Forecast

For the last 8 years the compound annual growth rate for Medtronic PLC's revenue is 6%. The projected CAGR for the next 4 years is 4%.

6%

4%

-1%

What are analyst estimates?

Operating Income
Forecast

For the last 8 years the compound annual growth rate for Medtronic PLC's operating income is 4%. The projected CAGR for the next 4 years is 12%.

4%

12%

-25%

What are analyst estimates?

Net Income
Forecast

For the last 8 years the compound annual growth rate for Medtronic PLC's net income is 4%. The projected CAGR for the next 4 years is 23%.

4%

23%

-38%

What are analyst estimates?

See Also

Relative Valuation

Wall Street Estimates

Profitability Analysis

Solvency Analysis

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

According to Wall Street analysts, the average 1-year price target for MDT is 95.99 USD with a low forecast of 75.75 USD and a high forecast of 109.2 USD.

For the last 8 years the compound annual growth rate for Medtronic PLC's revenue is 6%. The projected CAGR for the next 4 years is 4%.

For the last 8 years the compound annual growth rate for Medtronic PLC's operating income is 4%. The projected CAGR for the next 4 years is 12%.

For the last 8 years the compound annual growth rate for Medtronic PLC's net income is 4%. The projected CAGR for the next 4 years is 23%.

Join more than 133,500+ value investors using Alpha Spread

Create a free account

or see our plans & pricing

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

What is Intrinsic Value? Help Center Contact Us

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.